IRVINE, Calif., January 07, 2026--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Masimo (NASDAQ: MASI) today hosted its 2025 Investor Day at the Company’s headquarters. At the event, Masimo’s management team provided an update on the Company’s long-term strategy, including the ...

Files Revised Definitive Proxy Materials and Mails Letter to Stockholders Urges Stockholders to Vote “FOR” Only Masimo’s Director Nominees, Joe Kiani and Christopher Chavez, on the Updated GOLD Proxy ...

Masimo (MASI) is back in focus after recent trading left the shares around US$138.92, with returns that differ sharply across time frames, from a small move over the past month to a deeper decline ...

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient ...

Masimo has had a lot of distractions in the past couple years, between its high-profile patent battle against Apple plus tensions between CEO Joe Kiani and the board. In March, the company revealed ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Masimo (MASI).

Medical technology company Masimo has been facing off with Apple in court since 2020, and while Masimo has scored some wins, it's been an expensive endeavor. In its quarterly earnings reports, Masimo ...